Long-term Use and Safety of JAK Inhibitors and Evaluating Efficacy Outcomes in Atopic Dermatitis : Episode 11

Video

June 5, 2023

JAK Inhibitor Safety

Author(s):

Andrew Blauvelt, MD

A dermatology expert discusses taking a nuanced approach to interpreting the boxed warnings for JAK inhibitor for atopic dermatitis (AD) treatment.

EP: 1.Standard of Care in AD

EP: 2.Clinical Outcomes in AD Clinical Trials

EP: 3.EASI Scores in AD Treatment

EP: 4.NRS in AD Treatment

EP: 5.AD: Efficacy Outcomes

EP: 6.RAD 2023 AD Trial: Meta-Analysis Data

EP: 7.AD Clinical Approach: Switching Therapies

EP: 8.Topical and Systemic Treatments for AD

EP: 9.Pathophysiology of AD Treatments

EP: 10.Treatment Selection in AD

EP: 11.JAK Inhibitor Safety

EP: 12.AD Treatment: Upadacitinib

EP: 13.Switching Therapies in AD

Related Videos

Importance of Birch Triterpene Findings for Epidermolysis Bullosa, with Anna Bruckner, MD

Phase 3 Findings on Birch Triterpenes for Epidermolysis Bullosa, with Anna Bruckner, MD

3 experts are featured in this series.

3 experts are featured in this series.

Impact of Tapinarof Cream Approval for Atopic Dermatitis, with Adelaide Hebert, MD

3 experts are featured in this series.

3 experts are featured in this series.

3 experts are featured in this series.

3 experts are featured in this series.

Related Content

Related Content

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.